BNET Industries
Market Cap:$3.5M
Last Fiscal Year Sales:$25.0M
- Public
Dow Jones Description
Through our wholly owned subsidiary Ever Leader Holdings Limited ("Ever Leader"), we are a pharmaceutical company that identifies, discovers, develops and manufactures both conventional medications and Traditional Chinese Medicines ("TCMs") for the treatment of some of the largest common ailments and diseases (e.g., common cold, diabetes, cancer). We are also dedicated to the development, manufacturing and commercialization of gene therapy products. We own all of the capital stock of Ever Leader Holdings Limited, a holding company incorporated under the laws of Hong Kong SAR on October 29, 2005. Ever Leader owns 95% of the issued and outstanding capital stock of Hubei Tongji Benda Ebei Pharmaceutical Co., Ltd., a Sino-Foreign Equity Joint Venture company incorporated under the laws of the PRC. Benda Ebei owns: (i) 95% of the issued and outstanding capital stock of Jiangling Benda Pharmaceutical Co., Ltd., a company formed under the laws of the PRC; (ii) 95% of the issued and outstanding capital stock of Yidu Benda Chemical Co., Ltd., a company incorporated under the laws of the PRC; (iii) 75% of the issued and outstanding capital stock of Beijing Shusai Pharyngitis Research Co., Ltd., a company incorporated under the laws of the PRC; and (iv) 60.13% of the issued and outstanding capital stock of Shenzhen SiBiono Gene Technology Co., Ltd. ("SiBiono"), a company incorporated under the laws of the PRC. ...
Chief Executive Officer
Mark R LittellContact Information
4th Taibei Mingju, 6 Taibei Road,
Wuhan,
Hubei Province, 430015
86-27-8549 4916
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
benda pharmaceutical inc. - All News and Analysis
Enjoying Some Lunchtime News.
M2 PRESSWIRE-11 January 2008-Financialbusinessnews.us: Enjoying Some Lunchtime NewsC1994-2008 M2 COMMUNICATIONS LTD RDATE:11012008 Boston, MA -- FinancialBusinessNews' "Companies Of Interest": Comstock Homebuilding Companies, Inc. (NASDAQ: CHCI); Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN); Collexis Holdings,...
Benda Comments on Stock Price Decline
HUBEI PROVINCE, China -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine([R]), the world's first commercialized gene therapy medicine for the treatment of cancer, has provided the following comment regarding the stock's recent trading history:...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Mark R Littell | Chief Executive Officer |
| Eric Yu | Chief Financial Officer and Director |
| Eric Yu Tak Shing | Chief Financial Officer and Director |
| George Zhou | Chief Operating Officer |
| Hui Long | Vice President of Technology |
| Jingbo Wu | Vice President |
| Wei Xu | Vice President of Operations |
| Hui Xu | Manager |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Charles Mo | Chairman |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Chief Executive Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Chief Financial Officer and Director | Current |
| Pay-Ease | Financial Controller | Former |
| Private Placements Inc | Former |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Chief Financial Officer and Director | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Chief Operating Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Vice President of Technology | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Vice President of Operations | Current |
| The Technology Company, Inc. | Chairperson | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Manager | Current |
| Organization | Position | Status |
|---|---|---|
| Benda Pharmaceutical, Inc. | Chairman | Current |
| Amcham Shanghai | Board of Directors | Current |
| Volume | 0 |
| Shares Outstanding | 105.1M |
| Market Cap | 3.5M |
| Year High | 0.15 |
| Year Low | 0.0050 |
| Earnings Per Share | -0.050 |
| P/E Ratio | N/A |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
XOMA Ltd. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about XOMA
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
-
Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about MNTA
-
Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about EBS
-
Targacept, Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about TRGT
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Best Selling Drugs Will Soon be Biologics, But Not Owned by Biotechs 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


